|
|
Listeria monocytogenes LM1-2 vaccine vector |
|
Vaxvec ID |
16 |
|
Vaccine Vector Name |
Listeria monocytogenes LM1-2 vaccine vector |
|
Vector VO ID |
VO_0001041
|
|
Function |
The LM-1-2 strain of L. monocytogenes is able to express a human papillomavirus (a cause of cervical cancer) antigen, called E7. The L. monocytogenes therefore functions as a vehicle to transport the antigen in the host body, eliciting an immune response (Jia et al., 2012). |
|
Advantage |
This strain is able to elicit strong innate and adaptive immune responses against pathogenic challenges, making it a good candidate to be a cancer vaccine vector. It was also shown to provide long-lasting immunity after a second challenge (Jia et al., 2012). |
|
Safety |
The LM1-2 strain is highly attenuated, with the loss of the actA/plcB virulence factors, therefore making it a safe yet effective option for clinical use in cancer vaccines (Jia et al., 2012). |
|
Description |
The LM-1-2 strain of L. monocytogenes is able to express a human papillomavirus (a cause of cervical cancer) antigen, called E7. The L. monocytogenes therefore functions as a vehicle to transport the antigen in the host body, eliciting an immune response (Jia et al., 2012). |
| Related Vaccine(s) |
|
| References |
Jia et al., 2012: Jia Y, Yin Y, Duan F, Fu H, Hu M, Gao Y, Pan Z, Jiao X. Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model. International journal of molecular medicine. 2012; 30(6); 1335-1342. [PubMed: 23027427].
|
|
